GEFTIFER – Gefitinib Tablets IP 250 mg
Product Overview
GEFTIFER (Gefitinib Tablets IP 250 mg) is an oral targeted anticancer therapy containing Gefitinib 250 mg, an Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI). It is indicated for the treatment of adult patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumors have activating EGFR mutations.
GEFTIFER works by selectively inhibiting EGFR signaling, thereby slowing the growth and spread of cancer cells while helping preserve healthy tissues. Treatment should be initiated and monitored by an oncologist experienced in targeted cancer therapy.
| Attribute | Details |
|---|---|
| Brand Name | GEFTIFER |
| Generic Name | Gefitinib Tablets IP |
| Strength | 250 mg |
| Dosage Form | Film-Coated Tablets |
| Packaging | 1 × 10 Tablets |
| Therapeutic Category | Anticancer / EGFR Tyrosine Kinase Inhibitor |
| Route of Administration | Oral |
| Prescription Status | Prescription Medicine |
| Manufacturer | Pharmafer Pvt. Ltd. |
| Storage | Store below 30°C in a cool, dry place. Protect from moisture and direct sunlight. |
Uses of GEFTIFER
GEFTIFER is indicated for:
- Treatment of locally advanced Non-Small Cell Lung Cancer (NSCLC)
- Treatment of metastatic NSCLC with activating EGFR mutations
- First-line targeted therapy for eligible patients with EGFR mutation-positive NSCLC
- Treatment as prescribed by an oncology specialist according to established clinical guidelines
Benefits
Targeted Cancer Therapy
Specifically targets EGFR-mutated cancer cells, helping slow tumour growth while minimizing effects on normal cells.
Convenient Oral Administration
Once-daily oral tablet provides an alternative to intravenous cancer treatment for eligible patients.
Proven Clinical Effectiveness
Gefitinib is an established targeted therapy for EGFR mutation-positive NSCLC and is widely used in oncology practice.
Supports Personalized Cancer Care
Suitable for patients whose tumors have confirmed activating EGFR mutations, enabling precision treatment.
Trusted Oncology Medicine
Manufactured to high pharmaceutical quality standards to support oncologists and healthcare institutions.
Possible Side Effects
Like all medicines, GEFTIFER may cause side effects, although not everyone experiences them.
Common side effects include:
- Skin rash
- Acne-like eruptions
- Diarrhea
- Dry skin
- Nausea
- Loss of appetite
- Mouth ulcers
- Fatigue
- Elevated liver enzymes
Patients should immediately report symptoms such as severe diarrhea, breathing difficulties, persistent cough, or signs of liver dysfunction to their healthcare provider.
Mechanism of Action
Gefitinib selectively inhibits the Epidermal Growth Factor Receptor (EGFR) tyrosine kinase, blocking signaling pathways responsible for cancer cell growth, proliferation, and survival. By preventing EGFR activation, GEFTIFER helps slow disease progression in patients with EGFR mutation-positive NSCLC.
Dosage & Administration
- Take only as prescribed by your oncologist.
- Recommended dose is typically 250 mg once daily.
- May be taken with or without food.
- Swallow the tablet whole with water.
- Continue treatment for as long as advised by your healthcare provider.
- Do not discontinue therapy without consulting your physician.
Frequently Asked Questions
GEFTIFER is used to treat patients with EGFR mutation-positive locally advanced or metastatic Non-Small Cell Lung Cancer.
GEFTIFER blocks the EGFR tyrosine kinase enzyme, helping slow the growth and spread of cancer cells.
Take one tablet once daily, with or without food, exactly as prescribed by your oncologist.
Yes. GEFTIFER is intended for patients whose tumors have confirmed activating EGFR mutations.
Yes. As an oral targeted therapy, it can be taken at home according to your oncologist's treatment plan.
